Turning Point Brands (TPB) saw a significant decline of 15.5% this week, primarily driven by reports of the FDA’s hesitance to approve new nicotine pouch products. As the company has increasingly relied on this segment—showing a remarkable 266% revenue growth year-over-year last quarter—investor confidence has been shaken by concerns over potential regulatory roadblocks and the health implications of these products, particularly among younger demographics.
The nicotine pouch market has been a bright spot for Turning Point, contributing 34% of total revenues, but the recent FDA scrutiny raises questions about future growth. With net revenue projections for this category reaching $180 million to $190 million by 2026, any prolonged regulatory delays could dampen investor sentiment and impact overall earnings.
For market professionals, the current dip in TPB shares, now down 50% from their highs, may present a buying opportunity if one believes the FDA’s caution is a temporary hurdle rather than a long-term barrier.
Source: fool.com